Germany

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

BioNTech and Fosun to Develop mRNA Vaccine for COVID-19

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Fosun Pharma

Deal Size: $180.0 million Upfront Cash: $135.0 million

Deal Type: Collaboration March 16, 2020

Details:

The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162.

BioNTech SE

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

BioNTech intends to initiate clinical testing for BNT162 in late April 2020, as part of a global clinical development program in Germany, the United States and China for COVID-19.

CureVac

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

Lead Product(s): nCoV-2019 vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: CEPI

Deal Size: $34.0 million Upfront Cash: $8.3 million

Deal Type: Collaboration January 31, 2020

Details:

The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible for Protection against Corona virus.

Find

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Product Type

Companies

BioNTech SE

BioNTech and Fosun to Develop mRNA Vaccine for COVID-19

BioNTech SE

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

CureVac

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019